enGene's LEGEND Cohort 1 CR Rises to 56%, BLA Filing Set for Q4 2026
ENGN sits 35% above its 52-week low of $1.4 on elevated volume (3.4× avg).
Summary
enGene reported improved pivotal LEGEND Cohort 1 data for detalimogene — 56% complete response at any time and 43% estimated 12-month durability — and said FDA alignment clears it to start a BLA submission by year-end 2026, with about $245.8M of cash to fund it.
Key Events · Product Development and Regulatory · ENGN
-
Pivotal CR Rate Improves to 56%
Complete response at any time rose to 56% (CI: 47%, 65%) in 120 efficacy-evaluable patients versus 54% in the April 2026 analysis.
-
Durability and 12-Month CR Jump
Kaplan-Meier estimate of duration of response ≥12 months improved to 43% from 25%, median duration to 10.1 months from 8.6 months, and landmark 12-month CR to 24% from 13%.
-
FDA Aligns on Evaluable Population
A positive pre-BLA meeting produced alignment on the efficacy-evaluable population (125 trial patients less 5 exclusions = 120), clearing a key submission question.
-
BLA Filing Targeted for Q4 2026
enGene expects to initiate the BLA submission by year-end 2026, complete it in the first half of 2027, with potential FDA approval in 2027; surfactant cohort data expected mid-2027.
Analysis · ENGN · Life Sciences
This is the dataset enGene intends to file for approval, and every efficacy measure improved versus the April 2026 cut: CR at any time 56% vs 54%, 12-month landmark CR 24% vs 13%, and the Kaplan-Meier estimate of durability past 12 months 43% vs 25%. Just as important, the pre-BLA meeting with the FDA settled the efficacy-evaluable population (120 of 125 patients), removing a key ambiguity before submission. With roughly $245.8M of cash at October 31, the company says it is funded through the BLA filing and potential 2027 approval, so this is a clinical and regulatory de-risking event rather than a financing one. The remaining swing factor is durability, where nine patients are still pending their 12-month assessment.
How filings like this one have moved
In the 30 days to Nov 11, 2026, 48.1% of the 1752 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ENGN was trading at $1.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $120.6M. The 52-week trading range was $1.40 to $12.25. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.